Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

@article{Jni2004RiskOC,
  title={Risk of cardiovascular events and rofecoxib: cumulative meta-analysis},
  author={Peter J{\"u}ni and Linda Korkor Nartey and Stephan Reichenbach and Rebekka Sterchi and P. A. Dieppe and Matthias Egger},
  journal={The Lancet},
  year={2004},
  volume={364},
  pages={2021-2029}
}
View on Elsevier
cmgm.stanford.edu
808 Citations
Highly Influential Citations
30
Background Citations
201
Methods Citations
15
Results Citations
25

Figures and Tables from this paper

808 Citations

Risk of Cardiovascular Events and Celecoxib: a Systematic Review and Meta-Analysis
TLDR
The available data indicate an increased risk of myocardial infarction with celecoxib therapy, consistent with a class effect for COX-2 specific inhibitors.
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.
TLDR
The available data indicate an increased risk of myocardial infarction with celecoxib therapy, consistent with a class effect for COX-2 specific inhibitors.
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
TLDR
It is suggested that celecoxib in commonly used doses may not increase the risk, contradicts claims of a protective effect of naproxen, and raises serious questions about the safety of diclofenac, an older drug.
A Comparison of Reported Gastrointestinal and Thromboembolic Events Between Rofecoxib and Celecoxib Using Observational Data
TLDR
A retrospective comparison of PEM studies conducted for rofecoxib and celecoxib contributes to the understanding of the association between COX-2 inhibitors and thromboembolic events.
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
TLDR
Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups.
Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials
TLDR
The overall risk of myocardial infarction with NSAIDs and cyclo-oxygenase-2-specific drugs was small; rofecoxib showed the highest risk.
Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
TLDR
Use of NSAIDs or acetaminophen at high frequency or dose is associated with a significantly increased risk for major cardiovascular events, although more moderate use did not confer substantial risk.
Cardiovascular issues of COX-2 inhibitors and NSAIDs.
TLDR
The available evidence using a PubMed search for increased CV risk with COX-2 inhibitors and NSAIDs is reviewed, possible mechanisms are explored, and recommendations for their appropriate use in clinical practice are made.
Long-term Risk of Ischemic Stroke Associated with Rofecoxib
TLDR
Based on extended follow-up data, APPROVe is the first trial to report an increase in ischemic stroke risk with rofecoxib compared to placebo and should be further studied to determine whether patients previously exposed to rofECoxib remain at an increased risk.
COX 2 inhibitors, traditional NSAIDs, and the heart
TLDR
Rofecoxib had been marketed as the non-steroidal anti-inflammatory drug (NSAID) of choice because selective inhibition of the isoform 2 of the cyclooxygenase (COX 2) enzyme made it highly effective but free from gastrointestinal toxicity.
...
...

References

SHOWING 1-10 OF 47 REFERENCES
Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population
TLDR
The results do not support the existence of a clinically meaningful interaction between aspirin and NSAIDs, including ibuprofen, including aspirin taken concomitantly.
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
TLDR
The findings of this observational study suggest no increase in the short-term risk of AMI among users of selective cyclooxygenase 2 inhibitors as commonly used in clinical practice and do not support a short- term reduced risk ofAMI with naproxen.
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
TLDR
Current rofecoxib use was associated with an elevated relative risk of AMI compared with celecoxib use and no NSAID use, and Dosages of rofECoxib >25 mg were associated with a higher risk than dosages ≤25 mg, which was elevated in the first 90 days of use but not thereafter.
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
TLDR
The results of this study indicate that rofecoxib or low-dose naproxen does not slow cognitive decline in patients with mild-to-moderate AD.
Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study
Gastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis
TLDR
A pooled analysis of 8 efficacy trials in osteoarthritis and a large prospective study of outcomes in rheumatoid arthritis showed that rofecoxib maintained efficacy and resulted in a significantly lower incidence of serious GI toxicity compared with nonspecific dual COX inhibitors.
Association between naproxen use and protection against acute myocardial infarction.
TLDR
Compared with other NSAIDs, concurrent exposure to naproxen has a protective effect against acute myocardial infarction (AMI).
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.
TLDR
At 2-4 times the therapeutically effective dose, rofecoxib caused fewer endoscopically detected ulcers than did ibuprofen.
...
...